Á¦34Â÷ ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Ãá°èÇмú´ëȸ : 2019-04-26 |
|
Á¦34Â÷ ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Ãá°èÇмú´ëȸ : 2019-04-26 ±³À°ÀÏÀÚ : 2019-04-26 ±³À°Àå¼Ò : ºÎ»ê·Ôµ¥È£ÅÚ Å©¸®½ºÅ»º¼·ë ¿Ü ±³À°ÁÖÁ¦ : Á¦34Â÷ ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Ãá°èÇмú´ëȸ ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ ´ã´çÀÚ : ÀÌÇѳª ¿¬¶ôó : 02-512-5915 À̸ÞÀÏ : gyncancer@gyncancer.or.kr ±³À°Á¾·ù : »êºÎÀΰú Âü¼®¿¹»óÀοø : 400¸í Èñ¸ÁÆòÁ¡ : 6Á¡ Áö¿ª : ºÎ»ê±¤¿ª½Ã ±³À°½Ã°£ : 16 ½Ã°£ 10ºÐ ¼¼ºÎ¼ö°·á : 80,000¿ø ºñ°í Àü¹®ÀÇ : 8¸¸¿ø Àü°øÀÇ : 6¸¸¿ø ¿¬±¸¿ø/°£È£»ç : 4¸¸¿ø ÁÂÀå,¿¬ÀÚ,¸¸65¼¼ÀÌ»ó : ¹«·á ±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ ±âŸ 04-26 Å©¸®½ºÅ»º¼·ë 07:30~08:00 Registration .(.) ±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë 08:00~08:15 Post LACC trial status in other countries ÀÌÀ¯¿µ(¼º±Õ°üÀÇ´ë) ±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë 08:15~08:30 KSGO position statement on MIS in patients with early cervical cancer ±è¿ë¹ü(¼¿ïÀÇ´ë) Åä·Ð 04-26 Å©¸®½ºÅ»º¼·ë 08:30~08:50 Discussion (°øûȸ) () ±âŸ 04-26 Å©¸®½ºÅ»º¼·ë 08:50~09:10 °³È¸»ç ¹× ¸í¿¹È¸¿øÁõ ¼ö¿© ±è½Âö(ÀÌÈÀÇ´ë) ±âŸ 04-26 Å©¸®½ºÅ»º¼·ë 09:10~09:20 [Çмú´ë»ó] 1 topic .(.) ±âŸ 04-26 Å©¸®½ºÅ»º¼·ë 09:20~10:00 Plenary session 4 topics .(.) ±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë 10:00~10:10 KSGO-AOGIN young doctor program AOGIN ¿¬¼ö»ý(.) Åä·Ð 04-26 Å©¸®½ºÅ»º¼·ë 10:10~10:20 Discussion .(.) ÈÞ½Ä 04-26 Å©¸®½ºÅ»º¼·ë 10:20~10:40 Coffee break .(.) ±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë 10:40~11:10 LACC trial - impact in the US Warner Huh(SGO President) ±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë 11:10~11:40 Reappraisal of cervical adenocarcinoma treatments Nobuo Yaegashi(Tohoku University Japan) ±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë 11:40~12:10 TAGO clinical practice guidelines Hung-Hsueh Chou(Chang Gung University Taiwan) ±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë 12:10~12:40 Clonal expansion and diversification of cancer-associated mutations in endometriosis and normal endometrium Takayuki Enomoto(Niigata University Japan / JGOG President) ±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë 12:40~13:40 HPV test for primary screening for cervical cancer Tay Sun Kuie(Singapore General Hospital Singapore) Åä·Ð 04-26 Å©¸®½ºÅ»º¼·ë B 13:40~15:20 10 topics each: 8min presentation/2min discussion .(.) ÈÞ½Ä 04-26 Å©¸®½ºÅ»º¼·ë B 15:20~15:40 Coffee break .(.) ±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë B 15:40~16:00 Prediction of optimal cytoreductrive surgery in advanced ovarian cancer ÀÌ´ëÇü(¿µ³²ÀÇ´ë) ±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë B 16:00~16:20 Role of PARP inhibitor as front-line maintenance therapy in advanced ovarian cancer: SOLO-1 À¯ÇåÁ¾(Ãæ³²ÀÇ´ë) ±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë B 16:20~16:40 Combination treatment of PAPR inhibitor with other therapies in ovarian cancer : benefit and risk ÀÌÁ¤À±(¿¬¼¼ÀÇ´ë) Åä·Ð 04-26 Å©¸®½ºÅ»º¼·ë B 16:40~16:50 Discussion .(.) ±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë B 16:50~17:10 Treatment of ovarian cancer with PARP inhibitors: the importance of BRCA status ±Çº´¼ö(ºÎ»êÀÇ´ë) ±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë B 17:10~17:30 Real-world management of genetic counseling clinic in real practice ±è¹Ì°æ(ÀÌÈÀÇ´ë) ±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë B 17:30~17:50 Updated KSGO position statement for genetic testing & management ±è¹Ì¼±(Â÷ÀÇ´ë) Åä·Ð 04-26 Å©¸®½ºÅ»º¼·ë B 17:50~18:00 Discussion .(.) Åä·Ð 04-26 Å©¸®½ºÅ»º¼·ë C 13:40~15:20 10 topics each: 8min presentation/2min discussion .(.) ÈÞ½Ä 04-26 Å©¸®½ºÅ»º¼·ë C 15:20~15:40 Coffee break .(.) ±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë C 15:40~16:00 How to targeted therapy in platinum sensitive or resistance ovary cancer ÀÌ¿ø¹«(ÇѾçÀÇ´ë) ±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë C 16:00~16:20 Targeted agents and chemotherapy for endometrial cancer ¼ÛÀçÀ±(°í·ÁÀÇ´ë) ±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë C 16:20~16:40 Immunotherapy combination for HPV related cancer Çѽ¼ö(Áß¾ÓÀÇ´ë) Åä·Ð 04-26 Å©¸®½ºÅ»º¼·ë C 16:40~16:50 Discussion .(.) ±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë C 16:50~17:05 Key points of revised FIGO staging of cervical cancer 2018 ÀÌ´ë¿ì(°¡Å縯ÀÇ´ë) ±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë C 17:05~17:20 Impacts of revised FIGO staging 2018 on daily practice and research: Gynecologic Oncology Á¶µ¿ÈÞ(ÀüºÏÀÇ´ë) ±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë C 17:20~17:35 Impacts of revised FIGO staging 2018 on daily practice and research: Radiation Oncology ±èÁØ¿ø(¿¬¼¼ÀÇ´ë ¹æ»ç¼±Á¾¾çÇаú) ±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë C 17:35~17:50 Impacts of revised FIGO staging 2018 on daily practice and research: Cancer Epidemiology ¿ø¿µÁÖ(±¹¸³¾Ï¼¾ÅÍ ±¹Á¦¾Ï´ëÇпø´ëÇб³ ¾Ï°ü¸®Çаú) ±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë C 17:50~18:00 Discussion .(.) ±³À°½Ã°£ 04-26 ¿¡¸Þ¶öµå·ë 13:40~14:00 Fertility preservation in gynecologic oncology ÃÖÁø¿µ(ÃæºÏÀÇ´ë) ±³À°½Ã°£ 04-26 ¿¡¸Þ¶öµå·ë 14:00~14:20 Sentinel LN mapping in endometrial cancer ¹é¹ÎÇö(ÇѸ²ÀÇ´ë) ±³À°½Ã°£ 04-26 ¿¡¸Þ¶öµå·ë 14:20~15:10 Update on clinical trial in gynecologic oncology ½É½ÂÇõ(°Ç±¹ÀÇ´ë) Åä·Ð 04-26 ¿¡¸Þ¶öµå·ë 15:10~15:20 Discussion .(.) ÈÞ½Ä 04-26 ¿¡¸Þ¶öµå·ë 15:20~15:40 Coffee break .(.) ±³À°½Ã°£ 04-26 ¿¡¸Þ¶öµå·ë 15:40~16:10 IV management on gynecologic cancer ±è»óÈñ(»ï¼º¼¿ïº´¿ø Àü¹®°£È£»ç) ±³À°½Ã°£ 04-26 ¿¡¸Þ¶öµå·ë 16:10~16:40 Hypersensitivity management À¯¼±¿µ(¼¿ï¾Æ»êº´¿ø Àü¹®°£È£»ç) ±³À°½Ã°£ 04-26 ¿¡¸Þ¶öµå·ë 16:40~17:10 OCN guidance Á¶ÇýÁø(À̴뼿ﺴ¿ø Àü´ã°£È£»ç) ±³À°½Ã°£ 04-26 ¿¡¸Þ¶öµå·ë 17:10~17:40 Decision on life-sustaining treatment in gynecologic oncology ¿¹º´ÀÏ(¿¬¼¼¿øÁÖÀÇ´ë ÀÇÇб³À°ÇÐ) Åä·Ð 04-26 ¿¡¸Þ¶öµå·ë 17:40~18:00 Discussion .(.) |
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|